FindTrial
Sign In

Topical application of drugs to stop discomfort after canulation.

COMPARISON OF HEPARIN SODIUM TOPICAL SOLUTION AND DICLOFENAC SODIUM TOPICAL SOLUTION FOR PREVENTION OF THROMBOPHLEBITIS IN PATEINTS ADMITTED IN INTENSIVE CARE UNIT.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/10/010153
Enrollment
100
Registered
2017-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Any patient admitted in ICU Health Condition 2: K80- Cholelithiasis Health Condition 3: K80- Cholelithiasis

Interventions

Intervention1: Heparine QPS and Diclofenac QPS: applied superficially on skin surface over cannula. Control Intervention1: Heparine QPS and Diclofenac QPS: 5-6 drops of Heparine QPS and Diclofenac QPS

Sponsors

DR AKHILESHWAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Any patient being admitted to intensive care ward with intravenous cannula of less than 3 days or new intravenous canula has to be secured.

Exclusion criteria

Exclusion criteria: 1.Patients with history of deep vein thrombosis. 2.Patients receiving steroid, antiiflammatory agents or heparin.

Design outcomes

Primary

MeasureTime frame
development of Thrombophlebitis at canula insertion siteTimepoint: 5 DAYS post intravenous canulation—

Secondary

MeasureTime frame
Any adverse effect of drug.Timepoint: 5 DAYS post intravenous canulation—

Countries

India

Contacts

Public ContactDR AKHILESHWAR

INDIRA GANDHI INSTITIUTE OF MEDICAL SCIENCES

9.akhileshwar@gmail.com9835186989

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026